Literature DB >> 2795076

The effects of oral protein on the absorption of intraduodenal levodopa and motor performance.

J P Frankel1, P A Kempster, M Bovingdon, R Webster, A J Lees, G M Stern.   

Abstract

Four patients with levodopa induced fluctuations in motor performance were studied during the constant intraduodenal infusion of levodopa. The results confirm that steady plasma levodopa levels with stable motor control can be achieved. However, when patients were given oral protein loads, motor performance declined despite maintenance of plasma levodopa levels. These findings suggest that competition for levodopa carrier mediated transport by amino acids, is more important at the blood-brain barrier than across the gut mucosa; thereby possibly limiting the efficacy of long-term direct intraduodenal administration of levodopa.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795076      PMCID: PMC1031741          DOI: 10.1136/jnnp.52.9.1063

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier.

Authors:  L A Wade; R Katzman
Journal:  J Neurochem       Date:  1975-12       Impact factor: 5.372

2.  3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.

Authors:  L A Wade; R Katzman
Journal:  Life Sci       Date:  1975-07-01       Impact factor: 5.037

3.  Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography.

Authors:  K L Leenders; W H Poewe; A J Palmer; D P Brenton; R S Frackowiak
Journal:  Ann Neurol       Date:  1986-08       Impact factor: 10.422

4.  Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

Authors:  R Kurlan; A J Rubin; C Miller; L Rivera-Calimlim; A Clarke; I Shoulson
Journal:  Ann Neurol       Date:  1986-08       Impact factor: 10.422

5.  Dietary influences on the antiparkinsonian response to levodopa.

Authors:  J L Juncos; G Fabbrini; M M Mouradian; C Serrati; T N Chase
Journal:  Arch Neurol       Date:  1987-10

6.  Variability of L-dopa absorption in man.

Authors:  D N Wade; P T Mearrick; D J Birkett; J Morris
Journal:  Aust N Z J Med       Date:  1974-04

7.  "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.

Authors:  S Fahn
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

8.  Active transport of L-dopa in the intestine.

Authors:  D N Wade; P T Mearrick; J L Morris
Journal:  Nature       Date:  1973-04-13       Impact factor: 49.962

9.  'On-off' phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma.

Authors:  T Eriksson; A K Granérus; A Linde; A Carlsson
Journal:  Neurology       Date:  1988-08       Impact factor: 9.910

10.  Systemic activity of orally administered L-dopa in the elderly Parkinson patient.

Authors:  M A Evans; E J Triggs; G A Broe; N Saines
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

View more
  14 in total

1.  The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers.

Authors:  D R Robertson; I Higginson; B S Macklin; A G Renwick; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

2.  Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.

Authors:  C Brefel; C Thalamas; S Rayet; A Lopez-Gil; K Fitzpatrick; S Bullman; D R Citerone; A C Taylor; J L Montastruc; O Rascol
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

3.  Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension.

Authors:  J M Senard; B Chamontin; A Rascol; J L Montastruc
Journal:  Clin Auton Res       Date:  1992-04       Impact factor: 4.435

Review 4.  Drug treatment of Parkinson's disease in the 1990s. Achievements and future possibilities.

Authors:  A J Hughes
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 5.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum.

Authors:  D Nilsson; U Fagerholm; H Lennernäs
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

7.  The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man.

Authors:  H Lennernäs; D Nilsson; S M Aquilonius; O Ahrenstedt; L Knutson; L K Paalzow
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

8.  Drug therapy in patients with Parkinson's disease.

Authors:  Thomas Müller
Journal:  Transl Neurodegener       Date:  2012-05-24       Impact factor: 8.014

9.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

Review 10.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.